0001493152-23-024997.txt : 20230720 0001493152-23-024997.hdr.sgml : 20230720 20230720103546 ACCESSION NUMBER: 0001493152-23-024997 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b ITEM INFORMATION: Investment Company Act Section 3(c) ITEM INFORMATION: Section 3(c)(1) FILED AS OF DATE: 20230720 DATE AS OF CHANGE: 20230720 EFFECTIVENESS DATE: 20230720 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Life Sciences Innovation Fund II, L.P. CENTRAL INDEX KEY: 0001870508 IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-406537 FILM NUMBER: 231098453 BUSINESS ADDRESS: STREET 1: 527 MADISON AVENUE, SUITE 2600 CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: (212) 319-6625 MAIL ADDRESS: STREET 1: 527 MADISON AVENUE, SUITE 2600 CITY: NEW YORK STATE: NY ZIP: 10022 D/A 1 primary_doc.xml X0708 D/A LIVE 0001870508 Life Sciences Innovation Fund II, L.P. 527 MADISON AVENUE SUITE 2600 NEW YORK NY NEW YORK 10022 (212) 319-6625 DELAWARE None None Limited Partnership true 2021 - Life Sciences Innovation GP LLC 527 Madison Avenue Suite 2600 New York NY NEW YORK 10022 Executive Officer Director General Partner - AWM Investment Company, Inc. 527 Madison Avenue Suite 2600 New York NY NEW YORK 10022 Executive Officer Investment Manager David Sable c/o Life Sciences Innovation GP LLC 527 Madison Avenue, Suite 2600 New York NY NEW YORK 10022 Executive Officer Director Austin W Marxe c/o Life Sciences Innovation GP LLC 527 Madison Avenue, Suite 2600 New York NY NEW YORK 10022 Executive Officer Director David M Greenhouse c/o Life Sciences Innovation GP LLC 527 Madison Avenue, Suite 2600 New York NY NEW YORK 10022 Executive Officer Director President of AWM Investment Company, Inc. Adam Stettner c/o Life Sciences Innovation GP LLC 527 Madison Avenue, Suite 2600 New York NY NEW YORK 10022 Executive Officer Director Executive Vice President of AWM Investment Company, Inc. Pooled Investment Fund Other Investment Fund false Decline to Disclose 06b 3C 3C.1 true 0000905718-21-000918 2021-05-17 true true false 0 Indefinite 10808755 Indefinite false 38 0 true 0 true The Issuer may from time to time elect to engage third party broker dealers. Any commissions and/or expenses paid to such broker dealers will be paid by the General Partner out of net profits. 0 true The Investment Manager receives an asset based management fee. false Life Sciences Innovation Fund II, L.P. /s/ Adam Stettner Adam Stettner Authorized Signatory 2023-07-20